| ●Editorial | Nomoto M | 640 |
| ●The international conference in Matsuyama for promoting global clinical new drug developments ─ Agenda for global clinical trials in Asia ─ Organized by：Clinical Research Trial Center, Ehime University Hospital The Head of the Executive Committee：Nomoto M | 641-726 | |
| Opening remarks | Nomoto M | 643 |
| Current status and future perspectives in global/Asian clinical trials: PMDA reviewer's point of view | Shinagawa K | 644-53 |
| Clinical trials in Asian countries: Present and future | Mizuno Y | 654-61 |
| Current status and future perspectives in Asian clinical trials:Anti-dementia drugs | Homma A | 662-6 |
| Clinical trials in neurological disorders in Korea | Sohn YH | 667-75 |
| Global clinical studies in Asia: Philippines side | Rosales RL | 676-89 |
| Dosages and evidence on medicines in different countries, area or ethnics | Nomoto M | 690-6 |
| Medication use in Caucasian patients attending the Royal Adelaide Hospital Parkinson's Disease Clinic | Kimber T | 697-705 |
| Paths to sound discussions on dose setting of new drugs | Ono S | 706-12 |
| Exploratory clinical trials | Mayahara H | 713-9 |
| Early clinical trials in global development: Current status and problems that Japan faces | Uemura N | 720-4 |
| Closing remarks | Ohashi K | 725 |
| ●Consensus meeting for adipose tissue derived stem cell therapy Organized by：Translational Research Informatics Center, Foundation for Biomedical Research and Innovation | 727-815 | |
| Opening remarks Clinical development of stem cell therapy | Fukushima M | 729-38 |
| State of the art of adipose tissue stem cells | Ochiya T | 739-48 |
| Identification of adult human pluripotent stem cells that reside in mesenchymal tissues and their possible application to neurodegenerative and neurotraumatic diseases | Dezawa M | 749-60 |
| Dedifferentiated fat (DFAT) cells as a new cell source for regenerative medicine | Matsumoto T | 761-5 |
| Osteo-chondral regeneration by High Density Mesenchymal stem cell scaffold free Autologous Constructs (HD MACs) with ADRCs | Nakayama K | 766-8 |
| Application of MSC derived from fatty tissue to small size liver grafting | Kobayashi E，Fujimoto Y，Teratani T，Uemoto S | 769-74 |
| Data supporting clinical research with ADRCs: Answers to potential questions from IRBs and regulatory agencies | Fraser JK | 775-84 |
| Autologous bone marrow cell infusion therapy for liver cirrhosis | Sakaida I | 785-92 |
| Autologous adipose tissue derived stem cell therapy for stress urinary incontinence | Yamamoto T | 793-7 |
| Breast reconstruction and closure of therapy-resistant fistula | Tanaka F，Mimori K，Mori M，Hedrick MH | 798-803 |
| Aim to establish the periodontal tissue regeneration with adipose-derived stem cells | Tobita M | 804-7 |
| Fat grafting with adipose stromal cells | Yoshimura K | 808-14 |
| Summary | Fukushima M | 815 |
| ●Clinical Trial Project Management Seminar & Workshop: Health Labour Sciences Research Grant Project of ‘Promoting the establishment of clinical research (clinical trial) infrastructure' supported by The Ministry of Health Labour and Welfare Organized by：Clinical Pharmacology Center, Oita University Hospital， General Clinical Research Center, Oita University Hospital， Japan Clinical Pharmacology Network for Global Trials (J-CLIPNET) | 817-37 | |
| Introduction | Uemura N，Morimoto T，Suzaki Y | 818 |
| Challenges and prospects of project management of the clinical trial unit of a university hospital | Suzaki Y | 820-4 |
| Clinical research projects with academic and industry alliance | Inano A | 825-31 |
| A search for the most effective project management model in the pharmaceutical industry: Project Managers (PM) and Project Leaders (PL)-Do we need both? | Ohura CK | 832-7 |
| ●Articles | ||
| Education and training for ethics board members: Is e-learning the solution? | Tajima M，Nagamura F | 839-53 |
| Progress in human genome research prompts a paradigm shift in research ethics | Motojima M，Inoue I，Yonemoto S，Ichikawa I | 855-67 |
| Policy proposal for promoting clinical trials | Fukushima M，Ohno T，Matsuyama K，et al. | 869-84 |
| Do a small part of participating doctors contribute a large part of enrollment in clinical trials?: Validation of the Pareto's law in the CASE-J trial | Oe Y，Ueshima K，Oba K，et al. | 885-90 |
| ●Forum | ||
| Which is the more appropriate term, “antiepileptic drug” or “anticonvulsant”, for the therapeutic indication of a phenobarbital sodium injection? | Kamada I | 891-8 |
| Commentary | Inoue Y | 895-7 |
| ●Instructions for authors [Japanese] & [English] | 899-904 | |
| ●Editor's note | Tsutani K | 905 |